Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and Abiosciences, the single-cell bioinformatics leader, announced a new partnership to co-develop bioinformatics packages for translational and clinical research applications in hematological cancers

Mission Bio’s Tapestri® Platform is a powerful tool that has been adopted increasingly for translational research and clinical trials, both at biopharma companies and in academia. In the past month alone, presentations by gene therapy biotech AVROBIO at the Gene Therapy Analytical Development (GTAD) Summit and Servier Pharmaceuticals at the American Society of Hematology (ASH) Annual Meeting demonstrated the platform’s versatility in clinical trials, helping identify mechanisms of disease resistance in a Phase 3 trial and measuring critical quality attributes for clinical samples, respectively. Academic teams at ASH from City of Hope, Memorial Sloan Kettering Cancer Center, and more described a range of clinical research use cases for Tapestri®-based single-cell multi-omics assays, such as matching patients with leukemia to personalized care that reduced mortality in a clinical trial, and screening for dangerous cancer clones linked to therapeutic resistance.

Abiosciences will leverage its AI platform and bioinformatics expertise to create a unique and advanced bioinformatic analytical algorithm, in order to gain deeper and more comprehensive insights into disease progression, development of resistance, and  after single-cell multi-omics analysis for researchers in China. Mission Bio will support Abiosciences with its unique Tapestri single-cell multi-omics platform, custom panels, subject matter experts, and R&D expertise.

“Abiosciences has been committed to applying our single cell research platform and our big data/AI bioinformatics platform to unravel the complex heterogeneity underlying major diseases, such as cancer. Through the numerous algorithms and AI platforms exclusively developed by the company, we can more flexibly and effectively process the huge amount of data generated by single cell sequencing, find more valuable clinical therapeutic biomarkers, and help the translate the technology for clinical use,” said Tao Hong, Co-Founder & Chief Operating Officer at Abiosciences, “We are very happy to work with Mission Bio to provide more powerful technical support for clinical and translational researchers and implementation of single cell technology by combining our big data/AI platform of bioinformatics with Mission Bio’s single-cell multi-omics technology.”

“Elucidating tumor heterogeneity and clonal evolution are important to understand therapeutic resistance, and will be a crucial collaboration for the hematological oncology community,” said Yan Zhang, PhD, CEO of Mission Bio. “It also represents our continued efforts to support biotechnology companies in China that share our aim of transforming healthcare through collaboration and scientific advancement. We look forward to integrating our strength in single-cell multi-omics with Abiosciences’ complementary strengths in AI to advance analytical bioinformatics, and discover new biomarkers with potential clinical utility.”